SIMILAR PATTERN OF AMINO ACIDS MAPPED TO '4agu'

List of Similar Pattern of Amino Acids

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click on the DrReposER ID to view details on interfaces and similar patterns of amino acids)
(Click on the view link on the last column to view superposed patterns of amino acids)

Filter list by:

	DrReposER ID / Desc.	Hit PDBID	Hit Macromolecule	Res. Matches	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1FM6_D_BRLD503_1 (PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	5 / 12	GLY A 266 CYH A 267 LEU A 111 LEU A 201 LEU A 218	None	1.05A	1fm6D-4aguA: undetectable	1fm6D-4aguA: 22.32
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1T46_A_STIA3_1 (HOMO SAPIENS V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	8 / 12	VAL A 18 ALA A 31 LYS A 33 GLU A 51 LEU A 55 VAL A 64 LEU A 133 ASP A 144	D15 A 500 (-4.6A) D15 A 500 (-3.4A) D15 A 500 ( 4.1A) None None None D15 A 500 (-4.5A) D15 A 500 (-3.7A)	0.66A	1t46A-4aguA: 23.4	1t46A-4aguA: 24.79
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1UWH_A_BAXA1723_1 (B-RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	5 / 12	ALA A 31 GLU A 51 LEU A 55 CYH A 83 HIS A 124	D15 A 500 (-3.4A) None None D15 A 500 (-4.3A) None	0.35A	1uwhA-4aguA: 24.8	1uwhA-4aguA: 25.56
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1UWH_B_BAXB1723_1 (B-RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	6 / 12	ALA A 31 LYS A 33 GLU A 51 LEU A 55 CYH A 83 HIS A 124	D15 A 500 (-3.4A) D15 A 500 ( 4.1A) None None D15 A 500 (-4.3A) None	0.46A	1uwhB-4aguA: 24.6	1uwhB-4aguA: 25.56
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1UWJ_A_BAXA1723_1 (B-RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	5 / 12	VAL A 18 ALA A 31 GLU A 51 CYH A 83 HIS A 124	D15 A 500 (-4.6A) D15 A 500 (-3.4A) None D15 A 500 (-4.3A) None	0.39A	1uwjA-4aguA: 24.0	1uwjA-4aguA: 25.88
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1UWJ_B_BAXB1723_1 (B-RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	6 / 12	ILE A 10 VAL A 18 ALA A 31 GLU A 51 CYH A 83 HIS A 124	D15 A 500 (-4.2A) D15 A 500 (-4.6A) D15 A 500 (-3.4A) None D15 A 500 (-4.3A) None	0.64A	1uwjB-4aguA: 23.9	1uwjB-4aguA: 25.88
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2EUF_B_LQQB401_1 (CELL DIVISION PROTEIN KINASE 6)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	8 / 12	ILE A 10 VAL A 18 LYS A 33 VAL A 64 PHE A 80 ASN A 131 LEU A 133 ASP A 144	D15 A 500 (-4.2A) D15 A 500 (-4.6A) D15 A 500 ( 4.1A) None D15 A 500 ( 4.3A) D15 A 500 (-3.0A) D15 A 500 (-4.5A) D15 A 500 (-3.7A)	0.79A	2eufB-4aguA: 31.9	2eufB-4aguA: 36.42
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2FT9_A_CHDA130_0 (FATTY ACID-BINDING PROTEIN 2, LIVER)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	5 / 12	PHE A 192 VAL A 103 ILE A 290 HIS A 284 LEU A 263	None	1.18A	2ft9A-4aguA: undetectable	2ft9A-4aguA: 16.56
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2IVU_A_ZD6A3015_0 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET PRECURSOR)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	8 / 12	GLY A 11 VAL A 18 LYS A 33 GLU A 51 LEU A 55 LEU A 78 TYR A 82 LEU A 133	D15 A 500 (-3.8A) D15 A 500 (-4.6A) D15 A 500 ( 4.1A) None None None D15 A 500 (-4.8A) D15 A 500 (-4.5A)	0.63A	2ivuA-4aguA: 26.1	2ivuA-4aguA: 26.56
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2YQZ_A_SAMA301_1 (HYPOTHETICAL PROTEIN TTHA0223)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	4 / 5	TYR A 15 GLU A 130 ASP A 126 ASP A 184	D15 A 500 ( 4.1A) D15 A 500 ( 3.9A) None None	1.44A	2yqzA-4aguA: undetectable	2yqzA-4aguA: 22.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2YQZ_B_SAMB401_1 (HYPOTHETICAL PROTEIN TTHA0223)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	4 / 5	TYR A 15 GLU A 130 ASP A 126 ASP A 184	D15 A 500 ( 4.1A) D15 A 500 ( 3.9A) None None	1.46A	2yqzB-4aguA: undetectable	2yqzB-4aguA: 22.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3C7Q_A_XINA1172_1 (VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	7 / 12	GLY A 11 ALA A 31 LYS A 33 VAL A 64 CYH A 83 LEU A 133 CYH A 143	D15 A 500 (-3.8A) D15 A 500 (-3.4A) D15 A 500 ( 4.1A) None D15 A 500 (-4.3A) D15 A 500 (-4.5A) D15 A 500 ( 4.0A)	0.53A	3c7qA-4aguA: 22.3	3c7qA-4aguA: 27.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3FUP_B_MI1B1_1 (TYROSINE-PROTEIN KINASE JAK2)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	7 / 12	GLY A 11 GLY A 13 VAL A 18 ALA A 31 VAL A 64 TYR A 82 LEU A 133	D15 A 500 (-3.8A) D15 A 500 (-3.6A) D15 A 500 (-4.6A) D15 A 500 (-3.4A) None D15 A 500 (-4.8A) D15 A 500 (-4.5A)	0.47A	3fupB-4aguA: 24.9	3fupB-4aguA: 26.89
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3G0E_A_B49A9000_1 (MAST/STEM CELL GROWTH FACTOR RECEPTOR)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	7 / 11	VAL A 18 ALA A 31 VAL A 64 TYR A 82 CYH A 83 LEU A 133 CYH A 143	D15 A 500 (-4.6A) D15 A 500 (-3.4A) None D15 A 500 (-4.8A) D15 A 500 (-4.3A) D15 A 500 (-4.5A) D15 A 500 ( 4.0A)	0.63A	3g0eA-4aguA: 21.7	3g0eA-4aguA: 24.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3G0F_A_B49A9001_1 (MAST/STEM CELL GROWTH FACTOR RECEPTOR)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	6 / 11	VAL A 18 ALA A 31 TYR A 82 CYH A 83 LEU A 133 CYH A 143	D15 A 500 (-4.6A) D15 A 500 (-3.4A) D15 A 500 (-4.8A) D15 A 500 (-4.3A) D15 A 500 (-4.5A) D15 A 500 ( 4.0A)	0.68A	3g0fA-4aguA: 22.8	3g0fA-4aguA: 24.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3G0F_B_B49B9001_1 (MAST/STEM CELL GROWTH FACTOR RECEPTOR)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	6 / 10	VAL A 18 ALA A 31 TYR A 82 CYH A 83 LEU A 133 CYH A 143	D15 A 500 (-4.6A) D15 A 500 (-3.4A) D15 A 500 (-4.8A) D15 A 500 (-4.3A) D15 A 500 (-4.5A) D15 A 500 ( 4.0A)	0.62A	3g0fB-4aguA: 23.0	3g0fB-4aguA: 24.93
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3GP0_A_NILA1_1 (MITOGEN-ACTIVATED PROTEIN KINASE 11)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	6 / 12	VAL A 18 ALA A 31 GLU A 51 LEU A 55 HIS A 124 ASP A 144	D15 A 500 (-4.6A) D15 A 500 (-3.4A) None None None D15 A 500 (-3.7A)	0.96A	3gp0A-4aguA: 28.7	3gp0A-4aguA: 30.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3IK3_A_0LIA1_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	6 / 12	ALA A 31 GLU A 51 LEU A 63 VAL A 64 HIS A 124 LEU A 133	D15 A 500 (-3.4A) None None None None D15 A 500 (-4.5A)	0.60A	3ik3A-4aguA: 22.8	3ik3A-4aguA: 28.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3IK3_A_0LIA1_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	6 / 12	ALA A 31 GLU A 51 VAL A 64 HIS A 124 LEU A 133 ASP A 144	D15 A 500 (-3.4A) None None None D15 A 500 (-4.5A) D15 A 500 (-3.7A)	0.96A	3ik3A-4aguA: 22.8	3ik3A-4aguA: 28.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3IK3_B_0LIB2_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	6 / 12	ALA A 31 GLU A 51 LEU A 63 VAL A 64 HIS A 124 LEU A 133	D15 A 500 (-3.4A) None None None None D15 A 500 (-4.5A)	0.62A	3ik3B-4aguA: 22.5	3ik3B-4aguA: 28.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3LFA_A_1N1A361_1 (MITOGEN-ACTIVATED PROTEIN KINASE 14)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	4 / 8	ALA A 31 LYS A 33 GLU A 51 LEU A 78	D15 A 500 (-3.4A) D15 A 500 ( 4.1A) None None	0.32A	3lfaA-4aguA: 27.4	3lfaA-4aguA: 30.05
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3OG7_A_032A1_1 (AKAP9-BRAF FUSION PROTEIN)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	5 / 12	VAL A 18 ALA A 31 LYS A 33 LEU A 55 CYH A 83	D15 A 500 (-4.6A) D15 A 500 (-3.4A) D15 A 500 ( 4.1A) None D15 A 500 (-4.3A)	0.76A	3og7A-4aguA: 24.5	3og7A-4aguA: 24.10
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3RGF_A_BAXA465_1 (CYCLIN-DEPENDENT KINASE 8)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	7 / 12	VAL A 18 ALA A 31 GLU A 51 LEU A 55 PHE A 80 TYR A 82 HIS A 124	D15 A 500 (-4.6A) D15 A 500 (-3.4A) None None D15 A 500 ( 4.3A) D15 A 500 (-4.8A) None	0.72A	3rgfA-4aguA: 12.7	3rgfA-4aguA: 31.88
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3TBG_A_RTZA1_1 (CYTOCHROME P450 2D6)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	5 / 12	LEU A 249 PHE A 253 LEU A 196 GLY A 266 PHE A 287	None	1.22A	3tbgA-4aguA: undetectable	3tbgA-4aguA: 21.07
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3TI1_A_B49A299_1 (CYCLIN-DEPENDENT KINASE 2)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	5 / 9	ILE A 10 ALA A 31 VAL A 64 PHE A 80 LEU A 133	D15 A 500 (-4.2A) D15 A 500 (-3.4A) None D15 A 500 ( 4.3A) D15 A 500 (-4.5A)	0.74A	3ti1A-4aguA: 30.5	3ti1A-4aguA: 40.12
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3U9F_R_CLMR221_0 (CHLORAMPHENICOL ACETYLTRANSFERASE)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	5 / 10	TYR A 15 PHE A 35 PHE A 80 LEU A 133 VAL A 64	D15 A 500 ( 4.1A) None D15 A 500 ( 4.3A) D15 A 500 (-4.5A) None	1.49A	3u9fR-4aguA: undetectable	3u9fR-4aguA: 20.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3V5W_A_8PRA701_1 (G-PROTEIN COUPLED RECEPTOR KINASE 2)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	7 / 12	ILE A 10 GLY A 13 GLY A 16 VAL A 18 ALA A 31 LYS A 33 VAL A 64	D15 A 500 (-4.2A) D15 A 500 (-3.6A) D15 A 500 (-3.7A) D15 A 500 (-4.6A) D15 A 500 (-3.4A) D15 A 500 ( 4.1A) None	0.82A	3v5wA-4aguA: 11.0	3v5wA-4aguA: 19.60
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3V5W_A_8PRA701_1 (G-PROTEIN COUPLED RECEPTOR KINASE 2)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	7 / 12	ILE A 10 GLY A 16 VAL A 18 ALA A 31 LYS A 33 VAL A 64 LEU A 133	D15 A 500 (-4.2A) D15 A 500 (-3.7A) D15 A 500 (-4.6A) D15 A 500 (-3.4A) D15 A 500 ( 4.1A) None D15 A 500 (-4.5A)	1.09A	3v5wA-4aguA: 11.0	3v5wA-4aguA: 19.60
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3WZD_A_LEVA1201_1 (VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	6 / 12	GLY A 11 ALA A 31 GLU A 51 LEU A 55 CYH A 83 CYH A 143	D15 A 500 (-3.8A) D15 A 500 (-3.4A) None None D15 A 500 (-4.3A) D15 A 500 ( 4.0A)	0.77A	3wzdA-4aguA: 22.6	3wzdA-4aguA: 27.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3WZD_A_LEVA1201_1 (VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	6 / 12	VAL A 18 ALA A 31 GLU A 51 LEU A 55 CYH A 83 CYH A 143	D15 A 500 (-4.6A) D15 A 500 (-3.4A) None None D15 A 500 (-4.3A) D15 A 500 ( 4.0A)	0.68A	3wzdA-4aguA: 22.6	3wzdA-4aguA: 27.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3WZE_A_BAXA1201_2 (VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	5 / 8	VAL A 64 CYH A 83 LEU A 133 CYH A 143 ASP A 144	None D15 A 500 (-4.3A) D15 A 500 (-4.5A) D15 A 500 ( 4.0A) D15 A 500 (-3.7A)	0.62A	3wzeA-4aguA: 22.9	3wzeA-4aguA: 27.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	7 / 12	VAL A 18 ALA A 31 LYS A 33 GLU A 51 VAL A 64 LEU A 133 CYH A 143	D15 A 500 (-4.6A) D15 A 500 (-3.4A) D15 A 500 ( 4.1A) None None D15 A 500 (-4.5A) D15 A 500 ( 4.0A)	0.51A	4ag8A-4aguA: 22.8	4ag8A-4aguA: 27.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	7 / 12	VAL A 18 ALA A 31 LYS A 33 GLU A 51 LEU A 55 LEU A 133 CYH A 143	D15 A 500 (-4.6A) D15 A 500 (-3.4A) D15 A 500 ( 4.1A) None None D15 A 500 (-4.5A) D15 A 500 ( 4.0A)	0.60A	4agcA-4aguA: 22.2	4agcA-4aguA: 25.43
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4AGD_A_B49A2000_1 (VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	6 / 11	ALA A 31 LYS A 33 VAL A 64 CYH A 83 LEU A 133 CYH A 143	D15 A 500 (-3.4A) D15 A 500 ( 4.1A) None D15 A 500 (-4.3A) D15 A 500 (-4.5A) D15 A 500 ( 4.0A)	0.61A	4agdA-4aguA: 22.0	4agdA-4aguA: 25.43
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4AN2_A_EUIA1382_1 (DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	6 / 12	LEU A 78 LEU A 55 ASP A 126 LYS A 128 ASN A 131 GLY A 146	None None None D15 A 500 ( 4.8A) D15 A 500 (-3.0A) None	1.48A	4an2A-4aguA: 24.1	4an2A-4aguA: 28.80
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4ASD_A_BAXA1500_2 (VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	4 / 6	VAL A 64 CYH A 83 LEU A 133 CYH A 143	None D15 A 500 (-4.3A) D15 A 500 (-4.5A) D15 A 500 ( 4.0A)	0.28A	4asdA-4aguA: 22.5	4asdA-4aguA: 25.43
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4BKJ_A_STIA1000_1 (EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	6 / 12	VAL A 18 ALA A 31 GLU A 51 TYR A 82 LEU A 133 ASP A 144	D15 A 500 (-4.6A) D15 A 500 (-3.4A) None D15 A 500 (-4.8A) D15 A 500 (-4.5A) D15 A 500 (-3.7A)	0.87A	4bkjA-4aguA: 22.9	4bkjA-4aguA: 25.48
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4C8B_A_0LIA1000_1 (RECEPTOR-INTERACTING SERINE/THREONINE-PRO TEIN KINASE 2)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	7 / 12	ALA A 31 LYS A 33 GLU A 51 LEU A 55 HIS A 124 LEU A 133 ASP A 144	D15 A 500 (-3.4A) D15 A 500 ( 4.1A) None None None D15 A 500 (-4.5A) D15 A 500 (-3.7A)	0.82A	4c8bA-4aguA: 24.3	4c8bA-4aguA: 23.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4C8B_B_0LIB1000_1 (RECEPTOR-INTERACTING SERINE/THREONINE-PRO TEIN KINASE 2)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	7 / 12	ALA A 31 LYS A 33 GLU A 51 LEU A 55 HIS A 124 LEU A 133 ASP A 144	D15 A 500 (-3.4A) D15 A 500 ( 4.1A) None None None D15 A 500 (-4.5A) D15 A 500 (-3.7A)	0.92A	4c8bB-4aguA: 24.2	4c8bB-4aguA: 23.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4CKJ_A_ADNA2014_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	6 / 10	GLY A 11 GLY A 13 VAL A 18 ALA A 31 TYR A 82 LEU A 133	D15 A 500 (-3.8A) D15 A 500 (-3.6A) D15 A 500 (-4.6A) D15 A 500 (-3.4A) D15 A 500 (-4.8A) D15 A 500 (-4.5A)	0.54A	4ckjA-4aguA: 26.0	4ckjA-4aguA: 26.56
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4O0U_A_ADNA501_1 (AURORA KINASE A)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	4 / 6	VAL A 18 ALA A 31 LYS A 33 LEU A 133	D15 A 500 (-4.6A) D15 A 500 (-3.4A) D15 A 500 ( 4.1A) D15 A 500 (-4.5A)	0.63A	4o0uA-4aguA: 20.3	4o0uA-4aguA: 26.77
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4O0U_A_ADNA501_1 (AURORA KINASE A)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	4 / 6	VAL A 18 ALA A 31 THR A 86 LEU A 133	D15 A 500 (-4.6A) D15 A 500 (-3.4A) D15 A 500 ( 4.5A) D15 A 500 (-4.5A)	0.61A	4o0uA-4aguA: 20.3	4o0uA-4aguA: 26.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4OGR_A_ADNA401_1 (CYCLIN-DEPENDENT KINASE 9)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	5 / 8	ILE A 10 VAL A 18 ALA A 31 ASN A 131 LEU A 133	D15 A 500 (-4.2A) D15 A 500 (-4.6A) D15 A 500 (-3.4A) D15 A 500 (-3.0A) D15 A 500 (-4.5A)	0.60A	4ogrA-4aguA: 31.8	4ogrA-4aguA: 36.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4OGR_E_ADNE401_1 (CYCLIN-DEPENDENT KINASE 9)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	5 / 7	ALA A 31 CYH A 83 ASN A 131 LEU A 133 ASP A 144	D15 A 500 (-3.4A) D15 A 500 (-4.3A) D15 A 500 (-3.0A) D15 A 500 (-4.5A) D15 A 500 (-3.7A)	0.62A	4ogrE-4aguA: 31.2	4ogrE-4aguA: 36.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4OGR_I_ADNI401_1 (CYCLIN-DEPENDENT KINASE 9)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	6 / 9	ILE A 10 VAL A 18 ALA A 31 CYH A 83 ASN A 131 LEU A 133	D15 A 500 (-4.2A) D15 A 500 (-4.6A) D15 A 500 (-3.4A) D15 A 500 (-4.3A) D15 A 500 (-3.0A) D15 A 500 (-4.5A)	0.55A	4ogrI-4aguA: 31.6	4ogrI-4aguA: 36.39
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4R7I_A_STIA1001_1 (MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	8 / 12	VAL A 18 ALA A 31 LYS A 33 GLU A 51 CYH A 83 CYH A 122 LEU A 133 ASP A 144	D15 A 500 (-4.6A) D15 A 500 (-3.4A) D15 A 500 ( 4.1A) None D15 A 500 (-4.3A) None D15 A 500 (-4.5A) D15 A 500 (-3.7A)	0.73A	4r7iA-4aguA: 22.7	4r7iA-4aguA: 25.52
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4TYJ_A_0LIA801_1 (FIBROBLAST GROWTH FACTOR RECEPTOR 4)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	5 / 12	ALA A 31 GLU A 51 CYH A 122 HIS A 124 LEU A 133	D15 A 500 (-3.4A) None None None D15 A 500 (-4.5A)	0.65A	4tyjA-4aguA: 23.6	4tyjA-4aguA: 25.07
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4U0I_A_0LIA1001_2 (MAST/STEM CELL GROWTH FACTOR RECEPTOR KIT,MAST/STEM CELL GROWTH FACTOR RECEPTOR KIT)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	8 / 12	ALA A 31 LYS A 33 LEU A 55 CYH A 83 CYH A 122 HIS A 124 LEU A 133 CYH A 143	D15 A 500 (-3.4A) D15 A 500 ( 4.1A) None D15 A 500 (-4.3A) None None D15 A 500 (-4.5A) D15 A 500 ( 4.0A)	0.56A	4u0iA-4aguA: 23.2	4u0iA-4aguA: 24.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4U0I_A_0LIA1001_2 (MAST/STEM CELL GROWTH FACTOR RECEPTOR KIT,MAST/STEM CELL GROWTH FACTOR RECEPTOR KIT)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	8 / 12	ALA A 31 LYS A 33 LEU A 55 CYH A 83 HIS A 124 LEU A 133 CYH A 143 ASP A 144	D15 A 500 (-3.4A) D15 A 500 ( 4.1A) None D15 A 500 (-4.3A) None D15 A 500 (-4.5A) D15 A 500 ( 4.0A) D15 A 500 (-3.7A)	0.72A	4u0iA-4aguA: 23.2	4u0iA-4aguA: 24.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4XV2_A_P06A801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	5 / 12	VAL A 18 ALA A 31 LYS A 33 CYH A 83 PHE A 145	D15 A 500 (-4.6A) D15 A 500 (-3.4A) D15 A 500 ( 4.1A) D15 A 500 (-4.3A) None	0.66A	4xv2A-4aguA: 15.8	4xv2A-4aguA: 23.98
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4XV2_B_P06B801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	6 / 12	ALA A 31 LYS A 33 LEU A 55 CYH A 83 ASP A 144 PHE A 145	D15 A 500 (-3.4A) D15 A 500 ( 4.1A) None D15 A 500 (-4.3A) D15 A 500 (-3.7A) None	1.02A	4xv2B-4aguA: 24.4	4xv2B-4aguA: 23.98
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5CSW_A_P06A801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	5 / 12	VAL A 18 ALA A 31 LYS A 33 CYH A 83 PHE A 145	D15 A 500 (-4.6A) D15 A 500 (-3.4A) D15 A 500 ( 4.1A) D15 A 500 (-4.3A) None	0.70A	5cswA-4aguA: 23.9	5cswA-4aguA: 25.08
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5CSW_A_P06A801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	5 / 12	VAL A 18 ALA A 31 LYS A 33 LEU A 55 PHE A 145	D15 A 500 (-4.6A) D15 A 500 (-3.4A) D15 A 500 ( 4.1A) None None	0.87A	5cswA-4aguA: 23.9	5cswA-4aguA: 25.08
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5CSW_B_P06B801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	5 / 12	VAL A 18 ALA A 31 LYS A 33 CYH A 83 PHE A 145	D15 A 500 (-4.6A) D15 A 500 (-3.4A) D15 A 500 ( 4.1A) D15 A 500 (-4.3A) None	0.65A	5cswB-4aguA: 23.7	5cswB-4aguA: 25.08
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5CSW_B_P06B801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	5 / 12	VAL A 18 ALA A 31 LYS A 33 LEU A 55 PHE A 145	D15 A 500 (-4.6A) D15 A 500 (-3.4A) D15 A 500 ( 4.1A) None None	0.85A	5cswB-4aguA: 23.7	5cswB-4aguA: 25.08
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HES_B_032B401_1 (MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE MLT)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	6 / 12	VAL A 18 ALA A 31 LYS A 33 TYR A 82 CYH A 143 GLY A 146	D15 A 500 (-4.6A) D15 A 500 (-3.4A) D15 A 500 ( 4.1A) D15 A 500 (-4.8A) D15 A 500 ( 4.0A) None	1.02A	5hesB-4aguA: 22.8	5hesB-4aguA: 24.71
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HI2_A_BAXA801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	6 / 12	ALA A 31 LYS A 33 GLU A 51 LEU A 55 CYH A 83 HIS A 124	D15 A 500 (-3.4A) D15 A 500 ( 4.1A) None None D15 A 500 (-4.3A) None	0.55A	5hi2A-4aguA: 24.6	5hi2A-4aguA: 25.23
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HIE_A_P06A801_2 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	4 / 7	ILE A 10 GLY A 11 CYH A 83 PHE A 145	D15 A 500 (-4.2A) D15 A 500 (-3.8A) D15 A 500 (-4.3A) None	0.79A	5hieA-4aguA: 23.8	5hieA-4aguA: 23.58
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HIE_B_P06B801_2 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	4 / 7	ILE A 10 GLY A 11 CYH A 83 PHE A 145	D15 A 500 (-4.2A) D15 A 500 (-3.8A) D15 A 500 (-4.3A) None	0.81A	5hieB-4aguA: 23.6	5hieB-4aguA: 23.58
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HIE_D_P06D801_2 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	4 / 8	ILE A 10 GLY A 11 CYH A 83 PHE A 145	D15 A 500 (-4.2A) D15 A 500 (-3.8A) D15 A 500 (-4.3A) None	0.79A	5hieD-4aguA: 23.9	5hieD-4aguA: 23.58
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HM8_A_ADNA501_2 (ADENOSYLHOMOCYSTEINA SE)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	4 / 5	GLU A 247 THR A 217 GLU A 250 LEU A 196	None	1.25A	5hm8A-4aguA: undetectable	5hm8A-4aguA: 21.47
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HM8_B_ADNB501_2 (ADENOSYLHOMOCYSTEINA SE)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	4 / 5	GLU A 247 THR A 217 GLU A 250 LEU A 196	None	1.26A	5hm8B-4aguA: undetectable	5hm8B-4aguA: 21.47
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HM8_C_ADNC501_2 (ADENOSYLHOMOCYSTEINA SE)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	4 / 5	GLU A 247 THR A 217 GLU A 250 LEU A 196	None	1.26A	5hm8C-4aguA: undetectable	5hm8C-4aguA: 21.47
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HM8_D_ADND501_2 (ADENOSYLHOMOCYSTEINA SE)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	4 / 5	GLU A 247 THR A 217 GLU A 250 LEU A 196	None	1.25A	5hm8D-4aguA: undetectable	5hm8D-4aguA: 21.47
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HM8_E_ADNE501_2 (ADENOSYLHOMOCYSTEINA SE)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	4 / 5	GLU A 247 THR A 217 GLU A 250 LEU A 196	None	1.25A	5hm8E-4aguA: undetectable	5hm8E-4aguA: 21.47
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HM8_F_ADNF501_2 (ADENOSYLHOMOCYSTEINA SE)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	4 / 5	GLU A 247 THR A 217 GLU A 250 LEU A 196	None	1.26A	5hm8F-4aguA: undetectable	5hm8F-4aguA: 21.47
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HM8_H_ADNH501_2 (ADENOSYLHOMOCYSTEINA SE)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	4 / 5	GLU A 247 THR A 217 GLU A 250 LEU A 196	None	1.26A	5hm8H-4aguA: undetectable	5hm8H-4aguA: 21.47
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5I9Y_A_1N1A1001_1 (EPHRIN TYPE-A RECEPTOR 2)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	6 / 12	ILE A 10 ALA A 31 LYS A 33 GLU A 51 TYR A 82 LEU A 133	D15 A 500 (-4.2A) D15 A 500 (-3.4A) D15 A 500 ( 4.1A) None D15 A 500 (-4.8A) D15 A 500 (-4.5A)	0.76A	5i9yA-4aguA: 24.2	5i9yA-4aguA: 23.51
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5IZJ_F_AZ1F2_1 (CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA 47P-AZ1-DAR-DAR-DAR)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	4 / 7	GLY A 11 GLY A 13 GLY A 16 VAL A 18	D15 A 500 (-3.8A) D15 A 500 (-3.6A) D15 A 500 (-3.7A) D15 A 500 (-4.6A)	0.29A	5izjB-4aguA: 25.9	5izjB-4aguA: 24.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5IZJ_G_AZ1G2_1 (CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA 47P-AZ1-DAR-DAR)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	4 / 7	GLY A 11 GLY A 13 VAL A 18 LYS A 33	D15 A 500 (-3.8A) D15 A 500 (-3.6A) D15 A 500 (-4.6A) D15 A 500 ( 4.1A)	0.30A	5izjA-4aguA: 26.4	5izjA-4aguA: 24.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5J5X_B_AZ1B2_1 (CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA 47P-AZ1-DAL-DAR-DAR- DAR-DAR)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	4 / 7	GLY A 11 GLY A 13 VAL A 18 LYS A 33	D15 A 500 (-3.8A) D15 A 500 (-3.6A) D15 A 500 (-4.6A) D15 A 500 ( 4.1A)	0.41A	5j5xA-4aguA: 26.3	5j5xA-4aguA: 24.86
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5L2I_A_LQQA900_1 (CYCLIN-DEPENDENT KINASE 6)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	7 / 12	ILE A 10 GLY A 11 VAL A 18 ALA A 31 VAL A 64 PHE A 80 LEU A 133	D15 A 500 (-4.2A) D15 A 500 (-3.8A) D15 A 500 (-4.6A) D15 A 500 (-3.4A) None D15 A 500 ( 4.3A) D15 A 500 (-4.5A)	0.64A	5l2iA-4aguA: 16.4	5l2iA-4aguA: 35.54
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	7 / 12	ILE A 10 GLY A 11 VAL A 18 ALA A 31 VAL A 64 PHE A 80 LEU A 133	D15 A 500 (-4.2A) D15 A 500 (-3.8A) D15 A 500 (-4.6A) D15 A 500 (-3.4A) None D15 A 500 ( 4.3A) D15 A 500 (-4.5A)	0.75A	5l2tA-4aguA: 17.1	5l2tA-4aguA: 35.54
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5MO4_A_NILA601_2 (TYROSINE-PROTEIN KINASE ABL1)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	5 / 12	ALA A 31 LEU A 63 VAL A 64 HIS A 124 LEU A 133	D15 A 500 (-3.4A) None None None D15 A 500 (-4.5A)	0.52A	5mo4A-4aguA: 19.5	5mo4A-4aguA: 19.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5OWR_A_1N1A401_1 (SERINE/THREONINE-PRO TEIN KINASE 10)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	4 / 8	ALA A 31 GLU A 51 CYH A 83 LEU A 133	D15 A 500 (-3.4A) None D15 A 500 (-4.3A) D15 A 500 (-4.5A)	0.50A	5owrA-4aguA: 23.3	5owrA-4aguA: 28.03
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5OWR_A_1N1A401_1 (SERINE/THREONINE-PRO TEIN KINASE 10)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	4 / 8	GLU A 51 CYH A 83 LEU A 133 ASP A 144	None D15 A 500 (-4.3A) D15 A 500 (-4.5A) D15 A 500 (-3.7A)	0.74A	5owrA-4aguA: 23.3	5owrA-4aguA: 28.03
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5VCY_A_DB8A401_1 (MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	6 / 12	VAL A 18 ALA A 31 LYS A 33 GLU A 51 LEU A 78 CYH A 83	D15 A 500 (-4.6A) D15 A 500 (-3.4A) D15 A 500 ( 4.1A) None None D15 A 500 (-4.3A)	0.70A	5vcyA-4aguA: 26.8	5vcyA-4aguA: 24.04
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5YF9_B_NIOB401_1 (CASEIN KINASE II SUBUNIT ALPHA')	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	4 / 7	VAL A 18 LYS A 33 PHE A 80 ASP A 144	D15 A 500 (-4.6A) D15 A 500 ( 4.1A) D15 A 500 ( 4.3A) D15 A 500 (-3.7A)	0.88A	5yf9B-4aguA: 29.3	5yf9B-4aguA: 14.04
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5YU9_A_1E8A1101_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	6 / 12	GLY A 11 VAL A 18 ALA A 31 LYS A 33 LEU A 78 LEU A 133	D15 A 500 (-3.8A) D15 A 500 (-4.6A) D15 A 500 (-3.4A) D15 A 500 ( 4.1A) None D15 A 500 (-4.5A)	0.60A	5yu9A-4aguA: 22.2	5yu9A-4aguA: 13.62
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5YU9_B_1E8B1101_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	6 / 12	GLY A 11 VAL A 18 ALA A 31 LYS A 33 LEU A 78 LEU A 133	D15 A 500 (-3.8A) D15 A 500 (-4.6A) D15 A 500 (-3.4A) D15 A 500 ( 4.1A) None D15 A 500 (-4.5A)	0.65A	5yu9B-4aguA: 22.4	5yu9B-4aguA: 13.62

[["DrReposER ID","Desc.","Hit PDB","Hit molecule","Hit organism","Res. no.","Interface","HETATM","RMSD","Z-score","Seq ID"],["1FM6_D_BRLD503_1","PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",5,"GLY A 266;CYH A 267;LEU A 111;LEU A 201;LEU A 218","None","1.05A","1fm6D-4aguA:undetectable","1fm6D-4aguA:22.32"],["1T46_A_STIA3_1","HOMO SAPIENS V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",8,"VAL A  18;ALA A  31;LYS A  33;GLU A  51;LEU A  55;VAL A  64;LEU A 133;ASP A 144","D15 A 500 (-4.6A);D15 A 500 (-3.4A);D15 A 500 ( 4.1A);None;None;None;D15 A 500 (-4.5A);D15 A 500 (-3.7A)","0.66A","1t46A-4aguA:23.4","1t46A-4aguA:24.79"],["1UWH_A_BAXA1723_1","B-RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",5,"ALA A  31;GLU A  51;LEU A  55;CYH A  83;HIS A 124","D15 A 500 (-3.4A);None;None;D15 A 500 (-4.3A);None","0.35A","1uwhA-4aguA:24.8","1uwhA-4aguA:25.56"],["1UWH_B_BAXB1723_1","B-RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",6,"ALA A  31;LYS A  33;GLU A  51;LEU A  55;CYH A  83;HIS A 124","D15 A 500 (-3.4A);D15 A 500 ( 4.1A);None;None;D15 A 500 (-4.3A);None","0.46A","1uwhB-4aguA:24.6","1uwhB-4aguA:25.56"],["1UWJ_A_BAXA1723_1","B-RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",5,"VAL A  18;ALA A  31;GLU A  51;CYH A  83;HIS A 124","D15 A 500 (-4.6A);D15 A 500 (-3.4A);None;D15 A 500 (-4.3A);None","0.39A","1uwjA-4aguA:24.0","1uwjA-4aguA:25.88"],["1UWJ_B_BAXB1723_1","B-RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",6,"ILE A  10;VAL A  18;ALA A  31;GLU A  51;CYH A  83;HIS A 124","D15 A 500 (-4.2A);D15 A 500 (-4.6A);D15 A 500 (-3.4A);None;D15 A 500 (-4.3A);None","0.64A","1uwjB-4aguA:23.9","1uwjB-4aguA:25.88"],["2EUF_B_LQQB401_1","CELL DIVISION PROTEIN KINASE 6","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",8,"ILE A  10;VAL A  18;LYS A  33;VAL A  64;PHE A  80;ASN A 131;LEU A 133;ASP A 144","D15 A 500 (-4.2A);D15 A 500 (-4.6A);D15 A 500 ( 4.1A);None;D15 A 500 ( 4.3A);D15 A 500 (-3.0A);D15 A 500 (-4.5A);D15 A 500 (-3.7A)","0.79A","2eufB-4aguA:31.9","2eufB-4aguA:36.42"],["2FT9_A_CHDA130_0","FATTY ACID-BINDING PROTEIN 2, LIVER","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",5,"PHE A 192;VAL A 103;ILE A 290;HIS A 284;LEU A 263","None","1.18A","2ft9A-4aguA:undetectable","2ft9A-4aguA:16.56"],["2IVU_A_ZD6A3015_0","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET PRECURSOR","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",8,"GLY A  11;VAL A  18;LYS A  33;GLU A  51;LEU A  55;LEU A  78;TYR A  82;LEU A 133","D15 A 500 (-3.8A);D15 A 500 (-4.6A);D15 A 500 ( 4.1A);None;None;None;D15 A 500 (-4.8A);D15 A 500 (-4.5A)","0.63A","2ivuA-4aguA:26.1","2ivuA-4aguA:26.56"],["2YQZ_A_SAMA301_1","HYPOTHETICAL PROTEIN TTHA0223","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",4,"TYR A  15;GLU A 130;ASP A 126;ASP A 184","D15 A 500 ( 4.1A);D15 A 500 ( 3.9A);None;None","1.44A","2yqzA-4aguA:undetectable","2yqzA-4aguA:22.82"],["2YQZ_B_SAMB401_1","HYPOTHETICAL PROTEIN TTHA0223","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",4,"TYR A  15;GLU A 130;ASP A 126;ASP A 184","D15 A 500 ( 4.1A);D15 A 500 ( 3.9A);None;None","1.46A","2yqzB-4aguA:undetectable","2yqzB-4aguA:22.82"],["3C7Q_A_XINA1172_1","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",7,"GLY A  11;ALA A  31;LYS A  33;VAL A  64;CYH A  83;LEU A 133;CYH A 143","D15 A 500 (-3.8A);D15 A 500 (-3.4A);D15 A 500 ( 4.1A);None;D15 A 500 (-4.3A);D15 A 500 (-4.5A);D15 A 500 ( 4.0A)","0.53A","3c7qA-4aguA:22.3","3c7qA-4aguA:27.69"],["3FUP_B_MI1B1_1","TYROSINE-PROTEIN KINASE JAK2","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",7,"GLY A  11;GLY A  13;VAL A  18;ALA A  31;VAL A  64;TYR A  82;LEU A 133","D15 A 500 (-3.8A);D15 A 500 (-3.6A);D15 A 500 (-4.6A);D15 A 500 (-3.4A);None;D15 A 500 (-4.8A);D15 A 500 (-4.5A)","0.47A","3fupB-4aguA:24.9","3fupB-4aguA:26.89"],["3G0E_A_B49A9000_1","MAST\/STEM CELL GROWTH FACTOR RECEPTOR","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",7,"VAL A  18;ALA A  31;VAL A  64;TYR A  82;CYH A  83;LEU A 133;CYH A 143","D15 A 500 (-4.6A);D15 A 500 (-3.4A);None;D15 A 500 (-4.8A);D15 A 500 (-4.3A);D15 A 500 (-4.5A);D15 A 500 ( 4.0A)","0.63A","3g0eA-4aguA:21.7","3g0eA-4aguA:24.93"],["3G0F_A_B49A9001_1","MAST\/STEM CELL GROWTH FACTOR RECEPTOR","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",6,"VAL A  18;ALA A  31;TYR A  82;CYH A  83;LEU A 133;CYH A 143","D15 A 500 (-4.6A);D15 A 500 (-3.4A);D15 A 500 (-4.8A);D15 A 500 (-4.3A);D15 A 500 (-4.5A);D15 A 500 ( 4.0A)","0.68A","3g0fA-4aguA:22.8","3g0fA-4aguA:24.93"],["3G0F_B_B49B9001_1","MAST\/STEM CELL GROWTH FACTOR RECEPTOR","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",6,"VAL A  18;ALA A  31;TYR A  82;CYH A  83;LEU A 133;CYH A 143","D15 A 500 (-4.6A);D15 A 500 (-3.4A);D15 A 500 (-4.8A);D15 A 500 (-4.3A);D15 A 500 (-4.5A);D15 A 500 ( 4.0A)","0.62A","3g0fB-4aguA:23.0","3g0fB-4aguA:24.93"],["3GP0_A_NILA1_1","MITOGEN-ACTIVATED PROTEIN KINASE 11","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",6,"VAL A  18;ALA A  31;GLU A  51;LEU A  55;HIS A 124;ASP A 144","D15 A 500 (-4.6A);D15 A 500 (-3.4A);None;None;None;D15 A 500 (-3.7A)","0.96A","3gp0A-4aguA:28.7","3gp0A-4aguA:30.20"],["3IK3_A_0LIA1_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",6,"ALA A  31;GLU A  51;LEU A  63;VAL A  64;HIS A 124;LEU A 133","D15 A 500 (-3.4A);None;None;None;None;D15 A 500 (-4.5A)","0.60A","3ik3A-4aguA:22.8","3ik3A-4aguA:28.00"],["3IK3_A_0LIA1_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",6,"ALA A  31;GLU A  51;VAL A  64;HIS A 124;LEU A 133;ASP A 144","D15 A 500 (-3.4A);None;None;None;D15 A 500 (-4.5A);D15 A 500 (-3.7A)","0.96A","3ik3A-4aguA:22.8","3ik3A-4aguA:28.00"],["3IK3_B_0LIB2_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",6,"ALA A  31;GLU A  51;LEU A  63;VAL A  64;HIS A 124;LEU A 133","D15 A 500 (-3.4A);None;None;None;None;D15 A 500 (-4.5A)","0.62A","3ik3B-4aguA:22.5","3ik3B-4aguA:28.00"],["3LFA_A_1N1A361_1","MITOGEN-ACTIVATED PROTEIN KINASE 14","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",4,"ALA A  31;LYS A  33;GLU A  51;LEU A  78","D15 A 500 (-3.4A);D15 A 500 ( 4.1A);None;None","0.32A","3lfaA-4aguA:27.4","3lfaA-4aguA:30.05"],["3OG7_A_032A1_1","AKAP9-BRAF FUSION PROTEIN","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",5,"VAL A  18;ALA A  31;LYS A  33;LEU A  55;CYH A  83","D15 A 500 (-4.6A);D15 A 500 (-3.4A);D15 A 500 ( 4.1A);None;D15 A 500 (-4.3A)","0.76A","3og7A-4aguA:24.5","3og7A-4aguA:24.10"],["3RGF_A_BAXA465_1","CYCLIN-DEPENDENT KINASE 8","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",7,"VAL A  18;ALA A  31;GLU A  51;LEU A  55;PHE A  80;TYR A  82;HIS A 124","D15 A 500 (-4.6A);D15 A 500 (-3.4A);None;None;D15 A 500 ( 4.3A);D15 A 500 (-4.8A);None","0.72A","3rgfA-4aguA:12.7","3rgfA-4aguA:31.88"],["3TBG_A_RTZA1_1","CYTOCHROME P450 2D6","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",5,"LEU A 249;PHE A 253;LEU A 196;GLY A 266;PHE A 287","None","1.22A","3tbgA-4aguA:undetectable","3tbgA-4aguA:21.07"],["3TI1_A_B49A299_1","CYCLIN-DEPENDENT KINASE 2","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",5,"ILE A  10;ALA A  31;VAL A  64;PHE A  80;LEU A 133","D15 A 500 (-4.2A);D15 A 500 (-3.4A);None;D15 A 500 ( 4.3A);D15 A 500 (-4.5A)","0.74A","3ti1A-4aguA:30.5","3ti1A-4aguA:40.12"],["3U9F_R_CLMR221_0","CHLORAMPHENICOL ACETYLTRANSFERASE","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",5,"TYR A  15;PHE A  35;PHE A  80;LEU A 133;VAL A  64","D15 A 500 ( 4.1A);None;D15 A 500 ( 4.3A);D15 A 500 (-4.5A);None","1.49A","3u9fR-4aguA:undetectable","3u9fR-4aguA:20.38"],["3V5W_A_8PRA701_1","G-PROTEIN COUPLED RECEPTOR KINASE 2","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",7,"ILE A  10;GLY A  13;GLY A  16;VAL A  18;ALA A  31;LYS A  33;VAL A  64","D15 A 500 (-4.2A);D15 A 500 (-3.6A);D15 A 500 (-3.7A);D15 A 500 (-4.6A);D15 A 500 (-3.4A);D15 A 500 ( 4.1A);None","0.82A","3v5wA-4aguA:11.0","3v5wA-4aguA:19.60"],["3V5W_A_8PRA701_1","G-PROTEIN COUPLED RECEPTOR KINASE 2","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",7,"ILE A  10;GLY A  16;VAL A  18;ALA A  31;LYS A  33;VAL A  64;LEU A 133","D15 A 500 (-4.2A);D15 A 500 (-3.7A);D15 A 500 (-4.6A);D15 A 500 (-3.4A);D15 A 500 ( 4.1A);None;D15 A 500 (-4.5A)","1.09A","3v5wA-4aguA:11.0","3v5wA-4aguA:19.60"],["3WZD_A_LEVA1201_1","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",6,"GLY A  11;ALA A  31;GLU A  51;LEU A  55;CYH A  83;CYH A 143","D15 A 500 (-3.8A);D15 A 500 (-3.4A);None;None;D15 A 500 (-4.3A);D15 A 500 ( 4.0A)","0.77A","3wzdA-4aguA:22.6","3wzdA-4aguA:27.75"],["3WZD_A_LEVA1201_1","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",6,"VAL A  18;ALA A  31;GLU A  51;LEU A  55;CYH A  83;CYH A 143","D15 A 500 (-4.6A);D15 A 500 (-3.4A);None;None;D15 A 500 (-4.3A);D15 A 500 ( 4.0A)","0.68A","3wzdA-4aguA:22.6","3wzdA-4aguA:27.75"],["3WZE_A_BAXA1201_2","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",5,"VAL A  64;CYH A  83;LEU A 133;CYH A 143;ASP A 144","None;D15 A 500 (-4.3A);D15 A 500 (-4.5A);D15 A 500 ( 4.0A);D15 A 500 (-3.7A)","0.62A","3wzeA-4aguA:22.9","3wzeA-4aguA:27.75"],["4AG8_A_AXIA2000_1","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",7,"VAL A  18;ALA A  31;LYS A  33;GLU A  51;VAL A  64;LEU A 133;CYH A 143","D15 A 500 (-4.6A);D15 A 500 (-3.4A);D15 A 500 ( 4.1A);None;None;D15 A 500 (-4.5A);D15 A 500 ( 4.0A)","0.51A","4ag8A-4aguA:22.8","4ag8A-4aguA:27.69"],["4AGC_A_AXIA2000_1","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",7,"VAL A  18;ALA A  31;LYS A  33;GLU A  51;LEU A  55;LEU A 133;CYH A 143","D15 A 500 (-4.6A);D15 A 500 (-3.4A);D15 A 500 ( 4.1A);None;None;D15 A 500 (-4.5A);D15 A 500 ( 4.0A)","0.60A","4agcA-4aguA:22.2","4agcA-4aguA:25.43"],["4AGD_A_B49A2000_1","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",6,"ALA A  31;LYS A  33;VAL A  64;CYH A  83;LEU A 133;CYH A 143","D15 A 500 (-3.4A);D15 A 500 ( 4.1A);None;D15 A 500 (-4.3A);D15 A 500 (-4.5A);D15 A 500 ( 4.0A)","0.61A","4agdA-4aguA:22.0","4agdA-4aguA:25.43"],["4AN2_A_EUIA1382_1","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",6,"LEU A  78;LEU A  55;ASP A 126;LYS A 128;ASN A 131;GLY A 146","None;None;None;D15 A 500 ( 4.8A);D15 A 500 (-3.0A);None","1.48A","4an2A-4aguA:24.1","4an2A-4aguA:28.80"],["4ASD_A_BAXA1500_2","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",4,"VAL A  64;CYH A  83;LEU A 133;CYH A 143","None;D15 A 500 (-4.3A);D15 A 500 (-4.5A);D15 A 500 ( 4.0A)","0.28A","4asdA-4aguA:22.5","4asdA-4aguA:25.43"],["4BKJ_A_STIA1000_1","EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",6,"VAL A  18;ALA A  31;GLU A  51;TYR A  82;LEU A 133;ASP A 144","D15 A 500 (-4.6A);D15 A 500 (-3.4A);None;D15 A 500 (-4.8A);D15 A 500 (-4.5A);D15 A 500 (-3.7A)","0.87A","4bkjA-4aguA:22.9","4bkjA-4aguA:25.48"],["4C8B_A_0LIA1000_1","RECEPTOR-INTERACTING SERINE\/THREONINE-PROTEIN KINASE 2","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",7,"ALA A  31;LYS A  33;GLU A  51;LEU A  55;HIS A 124;LEU A 133;ASP A 144","D15 A 500 (-3.4A);D15 A 500 ( 4.1A);None;None;None;D15 A 500 (-4.5A);D15 A 500 (-3.7A)","0.82A","4c8bA-4aguA:24.3","4c8bA-4aguA:23.29"],["4C8B_B_0LIB1000_1","RECEPTOR-INTERACTING SERINE\/THREONINE-PROTEIN KINASE 2","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",7,"ALA A  31;LYS A  33;GLU A  51;LEU A  55;HIS A 124;LEU A 133;ASP A 144","D15 A 500 (-3.4A);D15 A 500 ( 4.1A);None;None;None;D15 A 500 (-4.5A);D15 A 500 (-3.7A)","0.92A","4c8bB-4aguA:24.2","4c8bB-4aguA:23.29"],["4CKJ_A_ADNA2014_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",6,"GLY A  11;GLY A  13;VAL A  18;ALA A  31;TYR A  82;LEU A 133","D15 A 500 (-3.8A);D15 A 500 (-3.6A);D15 A 500 (-4.6A);D15 A 500 (-3.4A);D15 A 500 (-4.8A);D15 A 500 (-4.5A)","0.54A","4ckjA-4aguA:26.0","4ckjA-4aguA:26.56"],["4O0U_A_ADNA501_1","AURORA KINASE A","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",4,"VAL A  18;ALA A  31;LYS A  33;LEU A 133","D15 A 500 (-4.6A);D15 A 500 (-3.4A);D15 A 500 ( 4.1A);D15 A 500 (-4.5A)","0.63A","4o0uA-4aguA:20.3","4o0uA-4aguA:26.77"],["4O0U_A_ADNA501_1","AURORA KINASE A","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",4,"VAL A  18;ALA A  31;THR A  86;LEU A 133","D15 A 500 (-4.6A);D15 A 500 (-3.4A);D15 A 500 ( 4.5A);D15 A 500 (-4.5A)","0.61A","4o0uA-4aguA:20.3","4o0uA-4aguA:26.77"],["4OGR_A_ADNA401_1","CYCLIN-DEPENDENT KINASE 9","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",5,"ILE A  10;VAL A  18;ALA A  31;ASN A 131;LEU A 133","D15 A 500 (-4.2A);D15 A 500 (-4.6A);D15 A 500 (-3.4A);D15 A 500 (-3.0A);D15 A 500 (-4.5A)","0.60A","4ogrA-4aguA:31.8","4ogrA-4aguA:36.39"],["4OGR_E_ADNE401_1","CYCLIN-DEPENDENT KINASE 9","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",5,"ALA A  31;CYH A  83;ASN A 131;LEU A 133;ASP A 144","D15 A 500 (-3.4A);D15 A 500 (-4.3A);D15 A 500 (-3.0A);D15 A 500 (-4.5A);D15 A 500 (-3.7A)","0.62A","4ogrE-4aguA:31.2","4ogrE-4aguA:36.39"],["4OGR_I_ADNI401_1","CYCLIN-DEPENDENT KINASE 9","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",6,"ILE A  10;VAL A  18;ALA A  31;CYH A  83;ASN A 131;LEU A 133","D15 A 500 (-4.2A);D15 A 500 (-4.6A);D15 A 500 (-3.4A);D15 A 500 (-4.3A);D15 A 500 (-3.0A);D15 A 500 (-4.5A)","0.55A","4ogrI-4aguA:31.6","4ogrI-4aguA:36.39"],["4R7I_A_STIA1001_1","MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",8,"VAL A  18;ALA A  31;LYS A  33;GLU A  51;CYH A  83;CYH A 122;LEU A 133;ASP A 144","D15 A 500 (-4.6A);D15 A 500 (-3.4A);D15 A 500 ( 4.1A);None;D15 A 500 (-4.3A);None;D15 A 500 (-4.5A);D15 A 500 (-3.7A)","0.73A","4r7iA-4aguA:22.7","4r7iA-4aguA:25.52"],["4TYJ_A_0LIA801_1","FIBROBLAST GROWTH FACTOR RECEPTOR 4","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",5,"ALA A  31;GLU A  51;CYH A 122;HIS A 124;LEU A 133","D15 A 500 (-3.4A);None;None;None;D15 A 500 (-4.5A)","0.65A","4tyjA-4aguA:23.6","4tyjA-4aguA:25.07"],["4U0I_A_0LIA1001_2","MAST\/STEM CELL GROWTH FACTOR RECEPTOR KIT,MAST\/STEM CELL GROWTH FACTOR RECEPTOR KIT","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",8,"ALA A  31;LYS A  33;LEU A  55;CYH A  83;CYH A 122;HIS A 124;LEU A 133;CYH A 143","D15 A 500 (-3.4A);D15 A 500 ( 4.1A);None;D15 A 500 (-4.3A);None;None;D15 A 500 (-4.5A);D15 A 500 ( 4.0A)","0.56A","4u0iA-4aguA:23.2","4u0iA-4aguA:24.72"],["4U0I_A_0LIA1001_2","MAST\/STEM CELL GROWTH FACTOR RECEPTOR KIT,MAST\/STEM CELL GROWTH FACTOR RECEPTOR KIT","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",8,"ALA A  31;LYS A  33;LEU A  55;CYH A  83;HIS A 124;LEU A 133;CYH A 143;ASP A 144","D15 A 500 (-3.4A);D15 A 500 ( 4.1A);None;D15 A 500 (-4.3A);None;D15 A 500 (-4.5A);D15 A 500 ( 4.0A);D15 A 500 (-3.7A)","0.72A","4u0iA-4aguA:23.2","4u0iA-4aguA:24.72"],["4XV2_A_P06A801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",5,"VAL A  18;ALA A  31;LYS A  33;CYH A  83;PHE A 145","D15 A 500 (-4.6A);D15 A 500 (-3.4A);D15 A 500 ( 4.1A);D15 A 500 (-4.3A);None","0.66A","4xv2A-4aguA:15.8","4xv2A-4aguA:23.98"],["4XV2_B_P06B801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",6,"ALA A  31;LYS A  33;LEU A  55;CYH A  83;ASP A 144;PHE A 145","D15 A 500 (-3.4A);D15 A 500 ( 4.1A);None;D15 A 500 (-4.3A);D15 A 500 (-3.7A);None","1.02A","4xv2B-4aguA:24.4","4xv2B-4aguA:23.98"],["5CSW_A_P06A801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",5,"VAL A  18;ALA A  31;LYS A  33;CYH A  83;PHE A 145","D15 A 500 (-4.6A);D15 A 500 (-3.4A);D15 A 500 ( 4.1A);D15 A 500 (-4.3A);None","0.70A","5cswA-4aguA:23.9","5cswA-4aguA:25.08"],["5CSW_A_P06A801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",5,"VAL A  18;ALA A  31;LYS A  33;LEU A  55;PHE A 145","D15 A 500 (-4.6A);D15 A 500 (-3.4A);D15 A 500 ( 4.1A);None;None","0.87A","5cswA-4aguA:23.9","5cswA-4aguA:25.08"],["5CSW_B_P06B801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",5,"VAL A  18;ALA A  31;LYS A  33;CYH A  83;PHE A 145","D15 A 500 (-4.6A);D15 A 500 (-3.4A);D15 A 500 ( 4.1A);D15 A 500 (-4.3A);None","0.65A","5cswB-4aguA:23.7","5cswB-4aguA:25.08"],["5CSW_B_P06B801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",5,"VAL A  18;ALA A  31;LYS A  33;LEU A  55;PHE A 145","D15 A 500 (-4.6A);D15 A 500 (-3.4A);D15 A 500 ( 4.1A);None;None","0.85A","5cswB-4aguA:23.7","5cswB-4aguA:25.08"],["5HES_B_032B401_1","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE MLT","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",6,"VAL A  18;ALA A  31;LYS A  33;TYR A  82;CYH A 143;GLY A 146","D15 A 500 (-4.6A);D15 A 500 (-3.4A);D15 A 500 ( 4.1A);D15 A 500 (-4.8A);D15 A 500 ( 4.0A);None","1.02A","5hesB-4aguA:22.8","5hesB-4aguA:24.71"],["5HI2_A_BAXA801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",6,"ALA A  31;LYS A  33;GLU A  51;LEU A  55;CYH A  83;HIS A 124","D15 A 500 (-3.4A);D15 A 500 ( 4.1A);None;None;D15 A 500 (-4.3A);None","0.55A","5hi2A-4aguA:24.6","5hi2A-4aguA:25.23"],["5HIE_A_P06A801_2","SERINE\/THREONINE-PROTEIN KINASE B-RAF","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",4,"ILE A  10;GLY A  11;CYH A  83;PHE A 145","D15 A 500 (-4.2A);D15 A 500 (-3.8A);D15 A 500 (-4.3A);None","0.79A","5hieA-4aguA:23.8","5hieA-4aguA:23.58"],["5HIE_B_P06B801_2","SERINE\/THREONINE-PROTEIN KINASE B-RAF","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",4,"ILE A  10;GLY A  11;CYH A  83;PHE A 145","D15 A 500 (-4.2A);D15 A 500 (-3.8A);D15 A 500 (-4.3A);None","0.81A","5hieB-4aguA:23.6","5hieB-4aguA:23.58"],["5HIE_D_P06D801_2","SERINE\/THREONINE-PROTEIN KINASE B-RAF","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",4,"ILE A  10;GLY A  11;CYH A  83;PHE A 145","D15 A 500 (-4.2A);D15 A 500 (-3.8A);D15 A 500 (-4.3A);None","0.79A","5hieD-4aguA:23.9","5hieD-4aguA:23.58"],["5HM8_A_ADNA501_2","ADENOSYLHOMOCYSTEINASE","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",4,"GLU A 247;THR A 217;GLU A 250;LEU A 196","None","1.25A","5hm8A-4aguA:undetectable","5hm8A-4aguA:21.47"],["5HM8_B_ADNB501_2","ADENOSYLHOMOCYSTEINASE","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",4,"GLU A 247;THR A 217;GLU A 250;LEU A 196","None","1.26A","5hm8B-4aguA:undetectable","5hm8B-4aguA:21.47"],["5HM8_C_ADNC501_2","ADENOSYLHOMOCYSTEINASE","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",4,"GLU A 247;THR A 217;GLU A 250;LEU A 196","None","1.26A","5hm8C-4aguA:undetectable","5hm8C-4aguA:21.47"],["5HM8_D_ADND501_2","ADENOSYLHOMOCYSTEINASE","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",4,"GLU A 247;THR A 217;GLU A 250;LEU A 196","None","1.25A","5hm8D-4aguA:undetectable","5hm8D-4aguA:21.47"],["5HM8_E_ADNE501_2","ADENOSYLHOMOCYSTEINASE","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",4,"GLU A 247;THR A 217;GLU A 250;LEU A 196","None","1.25A","5hm8E-4aguA:undetectable","5hm8E-4aguA:21.47"],["5HM8_F_ADNF501_2","ADENOSYLHOMOCYSTEINASE","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",4,"GLU A 247;THR A 217;GLU A 250;LEU A 196","None","1.26A","5hm8F-4aguA:undetectable","5hm8F-4aguA:21.47"],["5HM8_H_ADNH501_2","ADENOSYLHOMOCYSTEINASE","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",4,"GLU A 247;THR A 217;GLU A 250;LEU A 196","None","1.26A","5hm8H-4aguA:undetectable","5hm8H-4aguA:21.47"],["5I9Y_A_1N1A1001_1","EPHRIN TYPE-A RECEPTOR 2","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",6,"ILE A  10;ALA A  31;LYS A  33;GLU A  51;TYR A  82;LEU A 133","D15 A 500 (-4.2A);D15 A 500 (-3.4A);D15 A 500 ( 4.1A);None;D15 A 500 (-4.8A);D15 A 500 (-4.5A)","0.76A","5i9yA-4aguA:24.2","5i9yA-4aguA:23.51"],["5IZJ_F_AZ1F2_1","CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA;47P-AZ1-DAR-DAR-DAR","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",4,"GLY A  11;GLY A  13;GLY A  16;VAL A  18","D15 A 500 (-3.8A);D15 A 500 (-3.6A);D15 A 500 (-3.7A);D15 A 500 (-4.6A)","0.29A","5izjB-4aguA:25.9","5izjB-4aguA:24.86"],["5IZJ_G_AZ1G2_1","CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA;47P-AZ1-DAR-DAR","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",4,"GLY A  11;GLY A  13;VAL A  18;LYS A  33","D15 A 500 (-3.8A);D15 A 500 (-3.6A);D15 A 500 (-4.6A);D15 A 500 ( 4.1A)","0.30A","5izjA-4aguA:26.4","5izjA-4aguA:24.86"],["5J5X_B_AZ1B2_1","CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA;47P-AZ1-DAL-DAR-DAR-DAR-DAR","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",4,"GLY A  11;GLY A  13;VAL A  18;LYS A  33","D15 A 500 (-3.8A);D15 A 500 (-3.6A);D15 A 500 (-4.6A);D15 A 500 ( 4.1A)","0.41A","5j5xA-4aguA:26.3","5j5xA-4aguA:24.86"],["5L2I_A_LQQA900_1","CYCLIN-DEPENDENT KINASE 6","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",7,"ILE A  10;GLY A  11;VAL A  18;ALA A  31;VAL A  64;PHE A  80;LEU A 133","D15 A 500 (-4.2A);D15 A 500 (-3.8A);D15 A 500 (-4.6A);D15 A 500 (-3.4A);None;D15 A 500 ( 4.3A);D15 A 500 (-4.5A)","0.64A","5l2iA-4aguA:16.4","5l2iA-4aguA:35.54"],["5L2T_A_6ZZA900_1","CYCLIN-DEPENDENT KINASE 6","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",7,"ILE A  10;GLY A  11;VAL A  18;ALA A  31;VAL A  64;PHE A  80;LEU A 133","D15 A 500 (-4.2A);D15 A 500 (-3.8A);D15 A 500 (-4.6A);D15 A 500 (-3.4A);None;D15 A 500 ( 4.3A);D15 A 500 (-4.5A)","0.75A","5l2tA-4aguA:17.1","5l2tA-4aguA:35.54"],["5MO4_A_NILA601_2","TYROSINE-PROTEIN KINASE ABL1","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",5,"ALA A  31;LEU A  63;VAL A  64;HIS A 124;LEU A 133","D15 A 500 (-3.4A);None;None;None;D15 A 500 (-4.5A)","0.52A","5mo4A-4aguA:19.5","5mo4A-4aguA:19.66"],["5OWR_A_1N1A401_1","SERINE\/THREONINE-PROTEIN KINASE 10","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",4,"ALA A  31;GLU A  51;CYH A  83;LEU A 133","D15 A 500 (-3.4A);None;D15 A 500 (-4.3A);D15 A 500 (-4.5A)","0.50A","5owrA-4aguA:23.3","5owrA-4aguA:28.03"],["5OWR_A_1N1A401_1","SERINE\/THREONINE-PROTEIN KINASE 10","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",4,"GLU A  51;CYH A  83;LEU A 133;ASP A 144","None;D15 A 500 (-4.3A);D15 A 500 (-4.5A);D15 A 500 (-3.7A)","0.74A","5owrA-4aguA:23.3","5owrA-4aguA:28.03"],["5VCY_A_DB8A401_1","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",6,"VAL A  18;ALA A  31;LYS A  33;GLU A  51;LEU A  78;CYH A  83","D15 A 500 (-4.6A);D15 A 500 (-3.4A);D15 A 500 ( 4.1A);None;None;D15 A 500 (-4.3A)","0.70A","5vcyA-4aguA:26.8","5vcyA-4aguA:24.04"],["5YF9_B_NIOB401_1","CASEIN KINASE II SUBUNIT ALPHA'","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",4,"VAL A  18;LYS A  33;PHE A  80;ASP A 144","D15 A 500 (-4.6A);D15 A 500 ( 4.1A);D15 A 500 ( 4.3A);D15 A 500 (-3.7A)","0.88A","5yf9B-4aguA:29.3","5yf9B-4aguA:14.04"],["5YU9_A_1E8A1101_1","EPIDERMAL GROWTH FACTOR RECEPTOR","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",6,"GLY A  11;VAL A  18;ALA A  31;LYS A  33;LEU A  78;LEU A 133","D15 A 500 (-3.8A);D15 A 500 (-4.6A);D15 A 500 (-3.4A);D15 A 500 ( 4.1A);None;D15 A 500 (-4.5A)","0.60A","5yu9A-4aguA:22.2","5yu9A-4aguA:13.62"],["5YU9_B_1E8B1101_1","EPIDERMAL GROWTH FACTOR RECEPTOR","4agu","CYCLIN-DEPENDENT KINASE-LIKE 1","Homo sapiens",6,"GLY A  11;VAL A  18;ALA A  31;LYS A  33;LEU A  78;LEU A 133","D15 A 500 (-3.8A);D15 A 500 (-4.6A);D15 A 500 (-3.4A);D15 A 500 ( 4.1A);None;D15 A 500 (-4.5A)","0.65A","5yu9B-4aguA:22.4","5yu9B-4aguA:13.62"]]